115 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
in women undergoing in-vitro fertilization (“IVF”).
We in-licensed nolasiban from Ares Trading S.A., an affiliate of Merck Serono (“Merck Serono … the following:
Continue to advance the development program for nolasiban for the improvement of clinical pregnancy and live birth rates in women
6-K
EX-99.1
OBSVF
ObsEva SA
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
reproductive health and pregnancy. ObsEva has established a development program focused on improving clinical pregnancy and live birth rates in women undergoing
6-K
EX-99.1
OBSVF
ObsEva SA
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
on improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
medical needs.
Nolasiban is a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women
6-K
EX-99.3
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
rates in women undergoing in vitro fertilization, and we look forward to the initiation of our partner’s (Yuyuan BioScience) clinical trial following … receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva retains
6-K
EX-99.2
3vh93l64vvmkilkdcsm
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
ekgfcog3cwqfnv
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
EX-99.1
ye6logjs9jvmk
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
n7flbyq h4
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
EX-99.1
esy409
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K
EX-99.1
t39448d2rlgu
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
EX-99.2
d7mgno8
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.3
1z89 iljc8qnl
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
6pr6 m75zt4srn
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
fp5wid79f7nd
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
EX-99.1
vx2 ggo242
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.2
zhbe93i4lkpr7iau
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.1
3r11eakya3u40iy68
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
ol5splokt1quj kbymxa
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.2
yn7 wj3pdhjyexjxj
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am